Protein News and Research

RSS

Proteins are complex molecules that are made up of amino acids. They can be found in every cell in the body, and carry out vital processes that keep human beings alive. Mutations in proteins can lead to a multitude of diseases, the most common being cancer.

Sorrento Therapeutics acquires Concortis Biosystems

Sorrento Therapeutics, Inc. announced today that it has completed its acquisition of Concortis Biosystems, Corp., providing Sorrento with a comprehensive technology platform to create a new generation of homogenous antibody drug conjugates with site-specific toxin conjugation and consistent drug-antibody ratios. With the close of the deal, Sorrento has issued an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders. Based on the closing share price on December 18, 2013, the transaction is valued at $11.3 million.

19 Dec 2013

Researchers map cell's complex genetic interactions to fix UV damaged DNA

Researchers at the University of California, San Diego School of Medicine, with colleagues in The Netherlands and United Kingdom, have produced the first map detailing the network of genetic interactions underlying the cellular response to ultraviolet (UV) radiation.

19 Dec 2013

People with intermittent explosive disorder elevate levels of markers of systemic inflammation in blood

People with intermittent explosive disorder — a psychiatric illness characterized by impulsivity, hostility and recurrent aggressive outbursts — have elevated levels of two markers of systemic inflammation in their blood, according to a study involving nearly 200 subjects.

19 Dec 2013

New RUB project to unravel role of enzyme Parkin in promoting neuronal survival

Cell biologists at the Ruhr-Universit-t Bochum have launched a new project to unravel the role of the enzyme Parkin in promoting neuronal survival. The team of Prof Dr Konstanze F. Winklhofer from the Institute of Physiological Chemistry, Department of Molecular Cell Biology, is looking for new therapeutic options to treat Parkinson's disease. The Michael J. Fox Foundation finances this research project with 125,000 US Dollars.

18 Dec 2013

Researchers receive Special Challenge Award to investigate role of high protein levels in prostate tumors

Cleveland Clinic, along with the National Cancer Institute, the University of Chicago and Thomas Jefferson University, are the recipients of a $600,000 Special Challenge Award from the Prostate Cancer Foundation (PCF) to investigate the role of abnormally high protein levels in prostate tumors.

18 Dec 2013

Merck initiates clinical trial to evaluate MK-3475 and pazopanib in advanced renal cell carcinoma

Merck, known as MSD outside the United States and Canada, today announced the initiation of a clinical trial to evaluate the combination of the company's investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline's orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma.

18 Dec 2013

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for standard review the Company's supplemental Biologics License Application for EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema.

18 Dec 2013

Omeros' OMS721 receives FDA orphan drug designation for prevention of TMAs

Omeros Corporation today announced that OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system, has received orphan drug designation from the U.S. Food and Drug Administration for prevention of complement-mediated thrombotic microangiopathies.

18 Dec 2013

Researchers develop potential treatment for atherosclerosis

Researchers at Emory and Georgia Tech have developed a potential treatment for atherosclerosis that targets a master controller of the process.

18 Dec 2013

Octapharma enrolls first patients in GAM-27 Phase II/III clinical trial for relapsing multiple sclerosis

Octapharma AG, one of the largest global manufacturers of human proteins, today announced the enrolment of the first two patients in its GAM-27 Phase II/III clinical trial for the treatment of relapsing multiple sclerosis. Through intravenous administration of immunoglobulin (Octagam 5%), the study seeks to support the overall clinical benefit of a lower annualised relapse rate in patients where first-line treatment is not suitable.

18 Dec 2013

Innovation leads to faster drug therapies, increased understanding of proteins on microscopic level

Membrane proteins are the "gatekeepers" that allow information and molecules to pass into and out of a cell. Until recently, the microscopic study of these complex proteins has been restricted due to limitations of "force microscopes" that are available to researchers and the one-dimensional results these microscopes reveal.

17 Dec 2013

Measuring changes in certain proteins may better predict the progression of ALS

Measuring changes in certain proteins -- called biomarkers -- in people with amyotrophic lateral sclerosis may better predict the progression of the disease, according to scientists at Penn State College of Medicine.

17 Dec 2013

Arizona scientists investigate intriguing effects of spaceflight on microbial pathogens

At Arizona State University's Biodesign Institute, Cheryl Nickerson and her team have been investigating the intriguing effects of spaceflight on microbial pathogens.

17 Dec 2013

New gene mutation helps doctors give more accurate diagnosis of mitochondrial myopathy

A new gene mutation which will help doctors give a more accurate diagnosis of a particular type of brain and muscle disease in children has been discovered for the first time by University of Leeds experts.

17 Dec 2013

Addition of oregano oils to sunflower seeds preserves positive sensory attributes, freshness quality

Sunflower seeds and sunflower oils have been shown to decrease risk of cardiovascular disease as well as have potential beneficial effects on obesity, bone health, and blood pressure.

17 Dec 2013

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

BerGenBio AS, an oncology biopharmaceutical company, announces that preclinical data demonstrating that BGB324 has potential application as a novel treatment for Chronic Myeloid Leukemia, was presented in a poster at the Annual Meeting of the American Society of Hematology, which took place on December 7-10, 2013.

17 Dec 2013

Atara Biotherapeutics secures $38.5M in initial closings under Series B financing

Atara Biotherapeutics, Inc., a drug development company with a focus on innovative therapies for patients with debilitating diseases, announced today that it has secured $38.5 million in initial closings under its Series B financing. In this round, investors Amgen Ventures, Celgene Corporation, and EcoR1 Capital, joined existing investors Alexandria Venture Investments, DAG Ventures, Domain Associates, and Kleiner Perkins Caufield & Byers.

17 Dec 2013

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced results published from a Phase 2 study demonstrated that more than 90% of the patients treated with Prophage Series G-200 were alive at six months after surgery and 30% were alive at twelve months.

17 Dec 2013

Ipsen reports positive initial results from Dysport phase III study in Adult Upper Limb spasticity

Ipsen today announced positive initial results from the double-blind phase III study of Dysport (abobotulinumtoxinA) in Adult Upper Limb spasticity. Regarding the primary endpoints, treatment with Dysport showed statistically significant response versus placebo in the improvement of muscle tone, as measured by the Modified Ashworth Scale.

17 Dec 2013

Alnylam initiates Phase II study with ALN-TTRsc for treatment of ATTR

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a pilot Phase II study with ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting the transthyretin gene in development for the treatment of TTR-mediated amyloidosis.

17 Dec 2013

Protein News and Research

Further Reading

Sorrento Therapeutics acquires Concortis Biosystems

Researchers map cell's complex genetic interactions to fix UV damaged DNA

People with intermittent explosive disorder elevate levels of markers of systemic inflammation in blood

New RUB project to unravel role of enzyme Parkin in promoting neuronal survival

Researchers receive Special Challenge Award to investigate role of high protein levels in prostate tumors

Merck initiates clinical trial to evaluate MK-3475 and pazopanib in advanced renal cell carcinoma

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Omeros' OMS721 receives FDA orphan drug designation for prevention of TMAs

Researchers develop potential treatment for atherosclerosis

Octapharma enrolls first patients in GAM-27 Phase II/III clinical trial for relapsing multiple sclerosis

Innovation leads to faster drug therapies, increased understanding of proteins on microscopic level

Measuring changes in certain proteins may better predict the progression of ALS

Arizona scientists investigate intriguing effects of spaceflight on microbial pathogens

New gene mutation helps doctors give more accurate diagnosis of mitochondrial myopathy

Addition of oregano oils to sunflower seeds preserves positive sensory attributes, freshness quality

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

Atara Biotherapeutics secures $38.5M in initial closings under Series B financing

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

Ipsen reports positive initial results from Dysport phase III study in Adult Upper Limb spasticity

Alnylam initiates Phase II study with ALN-TTRsc for treatment of ATTR

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News